Icosagen was founded in 1999 and has grown into a leading mammalian Contract Research, Development, and Manufacturing Organization (CRDMO) for the biopharmaceutical, biotechnology, and diagnostic industries. Our seamless discovery, development, and manufacturing services cover up to early clinical candidate development, including stable CHO cell line development for 50L to 1000L GMP production runs. Our clients turn to us for custom-tailored solutions at every stage of the drug development process, including antibody and protein discovery for complicated proteins, and their multi-parallel recombinant production using CHO and HEK cell lines. In 2022, we worked with more than 100 protein drug or vaccine development companies globally, producing more than 3000 different proteins. As a company committed to staying at the forefront of bioprocessing technology, we are excited to showcase our upstream and downstream process development capabilities at the upcoming BioProcessing International conference.”